药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(20193620204934.PDF)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文ADVAIR HFA处方资料(仅供参考)
【英文名称】ADVAIR HFA
【适用证】
ADVAIR HFA是一种含有皮质类固醇和长效β2-肾上腺素能激动剂(LABA)的组合产品,适用于12岁及以上患者每日两次的哮喘治疗。
使用的重要限制:不适用于缓解急性支气管痉挛。
【剂量形式和强度】
吸入气溶胶:含有丙酸氟替卡松(45,115或230 mcg)和沙美特罗(21 mcg)的组合的吸入器,用作口服吸入的气溶胶制剂。
【用法用量】
•仅适用于口腔吸入。
•12岁及以上患者的哮喘治疗:每天两次吸入ADVAIR HFA 45/21,ADVAIR HFA 115/21或ADVAIR HFA 230/21。 起始剂量基于哮喘严重程度。
【禁忌症】
•需要采取强化措施的哮喘状态或哮喘急性发作的初级治疗。
•对任何成分过敏。
【INDICATIONS AND USAGE】
ADVAIR HFA is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for the twice-daily treatment of asthma in patients aged 12 years and older.
Important limitation of use: Not indicated for relief of acute bronchospasm.
【DOSAGE AND ADMINISTRATION】
• For oral inhalation only.
• Treatment of asthma in patients aged 12 years and older: 2 inhalations of ADVAIR HFA 45/21, ADVAIR HFA 115/21, or ADVAIR HFA 230/21 twice daily. Starting dosage is based on asthma severity.
【DOSAGE FORMS AND STRENGTHS】
Inhalation aerosol: Inhaler containing a combination of fluticasone propionate (45, 115, or 230 mcg) and salmeterol (21 mcg) as an aerosol formulation for oral inhalation.
【CONTRAINDICATIONS】
• Primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures.
• Hypersensitivity to any ingredient.
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(20193620204934.PDF)的“原文Priscribing Information”为准 --------------------------------------------------------------- |